Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
First in-human trials of rovalpituzumab for SCLC

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 1803

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Rudin speaks with ecancertv at ASCO 2016 about the results from a first in-human trial of rovalpituzumab, a delta-like protein 3 (DLL3) antibody-drug conjugate. 

DLL3 is highly expressed in neuroendocrine tumours, including approximately 80% of SCLC, which remains among the most deadly of malignancies.

Dr Rudin concludes that, with manageable toxicity, rovalpituzumab tesirine demonstrates encouraging single-agent anti-tumour activity and durability in recurrent or refractory SCLC, and he introduces a single-arm pivotal study in 3rd line DLL3-expressing SCLC. 

For more details, you can watch the announcement of these results at ASCO 2016 here.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation